← Leaderboards
Eric L Grogan
Veterans Health Administration
$4,673,710
Attributed
$9,247,427
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2012–25$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,147,434 · 2
AHRQ$99,993 · 1
VA$0 · 2
By mechanism
U01$6,111,684 · 1
R01$3,035,750 · 1
R03$99,993 · 1
I01$0 · 1
IK2$0 · 1
Top collaborators
- Stephen Deppen6 shared
- Anna E Baron5 shared
Most similar at Veterans Health Administration
Same institution · by research overlap
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungMalignant NeoplasmsImageEvaluationDiagnosisNoduleCohortProspectiveBenignLung NoduleBiological MarkersLung Cancer ScreeningValidationScreeningX-Ray Computed TomographyUniversitiesFutureCancer RiskBiopsyHigh RiskBloodSpecimenDiagnostic AccuracyLung
Grant awards (20)
Clinical Utility of a Combined Biomarker Approach to Diagnose Lung Cancer$1,904,653
U01 · FY2025 · CA · contact PI
Clinical Utility of Biomarkers Driven Management of Indeterminate Pulmonary Nodules$583,031
R01 · FY2025 · CA · contact PI
Creating a Veteran's specific risk model to improve lung cancer screening$0
I01 · FY2025 · VA · contact PI
Clinical Utility of a Combined Biomarker Approach to Diagnose Lung Cancer$774,532
U01 · FY2024 · CA · contact PI
Clinical Utility of Biomarkers Driven Management of Indeterminate Pulmonary Nodules$766,782
R01 · FY2024 · CA · contact PI
Creating a Veteran's specific risk model to improve lung cancer screening$0
I01 · FY2024 · VA · contact PI
Clinical Utility of a Combined Biomarker Approach to Diagnose Lung Cancer$1,001,446
U01 · FY2023 · CA · contact PI
Clinical Utility of Biomarkers Driven Management of Indeterminate Pulmonary Nodules$783,845
R01 · FY2023 · CA · contact PI
Creating a Veteran's specific risk model to improve lung cancer screening$0
I01 · FY2023 · VA · contact PI
Clinical Utility of a Combined Biomarker Approach to Diagnose Lung Cancer$853,805
U01 · FY2022 · CA · contact PI
Clinical Utility of Biomarkers Driven Management of Indeterminate Pulmonary Nodules$201,397
R01 · FY2022 · CA · contact PI
Clinical Utility of Biomarkers Driven Management of Indeterminate Pulmonary Nodules$700,695
R01 · FY2021 · CA · contact PI
Validation of Biomarkers of Risk for the Early Detection of Lung Cancer$554,708
U01 · FY2021 · CA · contact PI
Validation of Biomarkers of Risk for the Early Detection of Lung Cancer$1,022,540
U01 · FY2020 · CA · contact PI
Decreasing Unnecessary Invasive Lung Cancer Diagnostic Procedures$0
IK2 · FY2015 · VA · contact PI
Decreasing Unnecessary Invasive Lung Cancer Diagnostic Procedures$0
IK2 · FY2015 · VA · contact PI
Decreasing Unnecessary Invasive Lung Cancer Diagnostic Procedures$0
IK2 · FY2015 · VA · contact PI
Decreasing Unnecessary Invasive Lung Cancer Diagnostic Procedures$0
IK2 · FY2014 · VA · contact PI
Regional Variation of FDG-PET Scans to diagnose lung cancer$49,998
R03 · FY2013 · HS · contact PI
Regional Variation of FDG-PET Scans to diagnose lung cancer$49,995
R03 · FY2012 · HS · contact PI